Oditrasertib
SAR443820; DNL788
| Molecular Formula | C14H15F2N3O2 |
| Molecular Weight | 295.2846 |
- UNII-I1YQT8HC89
- I1YQT8HC89
- cas 2252271-93-3
- 4-(3,3-Difluoro-2,2-dimethylpropanoyl)-3,5-dihydro-2H-pyrido(3,4-F)(1,4)oxazepine-9-carbonitrile
PYRIDO(3,4-F)-1,4-OXAZEPINE-9-CARBONITRILE, 4-(3,3-DIFLUORO-2,2-DIMETHYL-1-OXOPROPYL)-2,3,4,5-TETRAHYDRO-
Oditrasertib is a serine/threonine kinase (STK) inhibitor.
Oditrasertib (SAR443820) is an orally active, BBB-penetrable and selective reversible inhibitor of RIPK1. Oditrasertib can be used in the research of chronic inflammatory central nervous system diseases, such as amyotrophic lateral sclerosis and multiple sclerosis.
SCHEME
SEE END OF PAGE
PATENT
[WO2018213632A1]
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018213632
AS ON DEC2021 3,491,869 VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
///////////Oditrasertib, SAR 443820, DNL 788
CC(C)(C(F)F)C(=O)N1CCOC2=C(C=NC=C2C1)C#N
WO2018213632
- [1]. Fidalgo JDV, et al. Preparation of substituted oxazepines and related compounds as RIPK1 inhibitors and uses thereof. WO2018213632A1. 2018-11-22.[2]. Hincelin-Mery A, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024 Jan;17(1):e13690. [Content Brief][3]. Montalban X, et al. Effect of RIPK1 inhibitor, SAR443820, on serum neurofilament light levels in patients with multiple sclerosis: a phase 2 trial design (P6-3.011)[J]. Neurology, 2023, 100(17_supplement_2): 2178.